EDEugenie Du

Eugenie Du

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eugenie Du has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Jose P. Zevallos

    Department of Otolaryngology, University of Pittsburgh Medical Center , Pittsburgh, PA

    2 shared publications
  • Mark C. Weissler

    Department of Otolaryngology‐Head and Neck Surgery University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

    2 shared publications
  • Andrew F. Olshan

    Department of Otolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, U.S.A.

    1 shared publication
  • Angela L. Mazul

    Department of Otolaryngology‐Head and Neck Surgery Washington University School of Medicine St. Louis Missouri USA

    1 shared publication
  • April Michelle Tanner

    Department of Otolaryngology‐Head and Neck Surgery University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

    1 shared publication
  • Behnoush Abedi‐Ardekani

    International Agency for Research on Cancer, Lyon, France

    1 shared publication

Latest Publications

  • A low-cost phantom for ultrasound-guided thyroid fine-needle aspiration training: face and construct validity

    by David Liao, Vikas Mehta, Eugenie Du, Vafa Tabatabaie, I. Martin Levy, Richard Smith, Marc Gibber


  • Decline in circulating viral and human tumor markers after resection of head and neck carcinoma

    by Erin M. Lopez, April Michelle Tanner, Eugenie Du, Samip N. Patel, Jared Weiss, Mark C. Weissler, Trevor Hackman, Gaorav P. Gupta, Jose Zevallos, Sandra Elmore, et al.

    Background: DNA sequencing panels can simultaneously quantify human and viral tumor markers in blood. We explored changes in levels of plasma tumor markers following surgical resection of head and neck carcinoma.Methods: In preresection and postresection plasmas, targeted DNA sequencing quantified variants in 28 human cancer genes and levels of oncogenic pathogens (human papillomavirus [HPV], Epstein‐Barr virus [EBV], Helicobacter pylori) from 21 patients with head and neck squamous cell carcinoma.Results: Preresection, 11 of 21 patients (52%) had detectable tumor markers in plasma, most commonly TP53 mutation or HPV genome. Several days postresection, levels fell to undetectable in 8 of 10 evaluable patients, while two high‐stage patients retained circulating tumor markers.Conclusions: Modern sequencing technology can simultaneously quantify human gene variants and oncogenic viral genomes in plasma. Falling levels of cancer‐specific markers upon resection can help identify viral and human markers to track at subsequent timepoints as a means to evaluate efficacy of interventions.


  • Dual‐phase CT angiography for presurgical planning in patients with vessel‐depleted neck

    by Eugenie Du, Sagar Patel, Benjamin Huang, Samip N. Patel

    Background: Microvascular reconstruction in vessel‐depleted necks is challenging due to limited availability of recipient vessels. We examine the utility of dual‐phase CT angiography (CTA), which delineates both arteries and veins, for preoperative planning in such difficult cases.Methods: Retrospective chart review of a single surgeon from July 2013 to July 2017 in a tertiary referral center was performed. Patient characteristics, operative details, and surgical outcomes were examined.Results: Thirteen patients met inclusion criteria. The operative plan was changed to a local flap for one patient as a result of imaging; free tissue transfer was performed for the remaining cases with 100% flap survival rate. Average operative time and ischemia time were 524 ± 110 minutes and 153 ± 47 minutes, respectively.Conclusions: Dual‐phase CTA can evaluate potential venous and arterial recipient vessel and guide surgical explorations. As such, it may aid in presurgical planning for microvascular free tissue transfer in vessel‐depleted necks.


  • Top Cited Papers

    Long‐term Survival in Head and Neck Cancer: Impact of Site, Stage, Smoking, and Human Papillomavirus Status

    by Eugenie Du, Angela L. Mazul, Doug Farquhar, Paul Brennan, Devasena Anantharaman, Behnoush Abedi‐Ardekani, Mark C. Weissler, David N. Hayes, Andrew F. Olshan, Jose P. Zevallos

    Objectives/Hypothesis: Literature examining long‐term survival in head and neck squamous cell carcinoma (HNSCC) with human papillomavirus (HPV) status is lacking. We compare 10‐year overall survival (OS) rates for cases to population‐based controls.Study Design: Prospective cohort study.Methods: Cases surviving 5 years postdiagnosis were identified from the Carolina Head and Neck Cancer Study. We examined 10‐year survival by site, stage, p16, and treatment using Kaplan‐Meier and Cox proportional hazard models. Cases were compared to age‐matched, noncancer controls with stratification by p16 and smoking status.Results: Ten‐year OS for HNSCC is less than controls. In 581 cases, OS differed between sites with p16+ oropharynx having the most favorable prognosis (87%), followed by oral cavity (69%), larynx (67%), p16− oropharynx (56%), and hypopharynx (51%). Initial stage, but not treatment, also impacted OS. When compared to controls matched on smoking status, the hazard ratio (HR) for death in p16+ oropharynx cases was 1.5 (95% confidence interval [CI]: 0.7‐3.1) for smokers and 2.4 (95% CI: 0.7‐8.8) for nonsmokers. Similarly, HR for death in non–HPV‐associated HNSCC was 2.2 (95% CI: 1.7‐3.0) for smokers and 2.4 (95% CI: 1.4‐4.9) for nonsmokers.Conclusions: OS for HNSCC cases continues to decrease 5 years posttreatment, even after stratification by p16 and smoking status. Site, stage, smoking, and p16 status are significant factors. These data provide important prognostic information for HNSCC.Level of Evidence: 2 Laryngoscope, 129:2506–2513, 2019